5 August 2024
IXICO
plc
("IXICO"
or the "Company")
Appointment of CEO
IXICO plc (AIM: IXI), the
precision analytics company delivering intelligent
insights in neuroscience, is pleased to announce that Bram Goorden
will be appointed as Chief Executive Officer of the Company from 19
August 2024.
Bram has over 20 years leadership
experience in BioPharma and precision medicine, serving in roles
where he has been instrumental in shaping commercial strategies for
scale, growing revenues and ultimately enabling realisation of
shareholder value. He has strong CNS experience, and established
networks within IXICO's target market bringing sector relevant
strength to IXICO.
Bram joins having recently held
C-level roles at Eagle Genomics Limited where he drove key industry
alliances for their AI platform and NASDAQ listed SOPHiA Genetics
Inc where he expanded their US footprint and delivered key
alliances with Pharma. In previous roles as VP International
Business, he expanded Foundation Medicine Inc's global presence in
precision medicine including programs with major BioPharma
partners, and as division CEO of US-based Prometheus Laboratories
he delivered shareholder value via the integration of the company
into Nestle Health Science SA. Bram has also held senior management
positions within UCB Pharma SA and Eli Lilly & Co, both in the
field of CNS medicine.
Bram's neuroscience experience is
demonstrated at Board level through current and past roles at
Mantis Photonics AB, a company providing a non-invasive method of
detecting neuro-degenerative diseases through retinal image
biomarker analysis and Cerecin Inc, a clinical development company
focused on therapeutic approaches to treat neurodegenerative
diseases. Bram started his career as a management consultant at
Accenture.
Bram's appointment follows the
announcement made on 12 January 2024, of Giulio Cerroni's intention
to retire from his role as CEO by the end of 2024. Giulio will step
down as a director of the Company on 16 August 2024. Giulio
continues to be available to the Company to support an orderly hand
over.
Mark Warne, Chair of the Board,
commented: "I am delighted to welcome Bram to the Board
as our CEO. Bram has significant track record in
the commercial application of AI precision medicine solutions that
is complemented by technical knowledge within neurodegenerative
diseases. As IXICO looks to return to growth, Bram's
experiences provide excellent credentials to ensure IXICO also
realises shareholder value.
I would like to thank Giulio for his valuable contributions over
many years. Having joined IXICO in 2017, Giulio steered the company
through a period of both strong growth and more challenging trading
conditions. He has overseen the development of the company's
science and technology portfolio which, in combination with IXICO's
operational capabilities, ensure the consistent delivery of leading
services to the CNS clinical trials
market."
Further disclosures required under
the AIM Rules
In addition to his appointment to
the Ixico Board, Bram Goorden, aged 50, holds or has held the
following directorships or partnerships in the past five
years. Bram currently holds no shares in the
Company.
|
Current
|
Previous
|
|
Oncobit AG
|
SOPHIA Genetics SA
|
|
Mantis Photonics AB
|
SOPHIA Genetics Inc
|
|
|
De Bonte Leeuw Inc
|
For further information please
contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated
Adviser and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks/Harriet Ward (Corporate
Broking)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews